Cytodyn Inc (CYDY)

[kgromax]

Yep I am pretty sure. The paper I posted clearly shows a big mortality jump when CRP goes from 50 to 100.
Several papers have also shown CRP is the BEST SINGLE VARIABLE to assess the severity of COVID for a patient. Better than age, comorbidities or any other predictor.
Filtering on CRP>75 as the Toci study did rejected low-risk patients as the statistics demonstrate.
That, plus the fact that Cytodyn rejected high-risk patients (inclusion criteria n°3 in Cytodyn's study) explains why Cytodyn's study is selecting on average much lower risk patients than the Toci's study. So mortality will be below Toci's study, by a 3% + 3% = 6% gap as I estimated in my posts based on available research papers. Said otherwise, Cytodyn's trial shall failed as this will bring back Cytodyn's placebo arm mortality too close to thee Leronlimab arm mortality for any statistical significance to be reached.